Literature DB >> 17571902

Fc glycans terminated with N-acetylglucosamine residues increase antibody resistance to papain.

T Shantha Raju1, Bernard Scallon.   

Abstract

Glycosylation in the CH2 domain of Fc is required for immunoglobulins G (IgGs) to exhibit immune effector functions including complement-dependent cytotoxicity (CDC) and antibody-dependent (Ab-dependent) cellular cytotoxicity (ADCC). We recently established that glycosylated Abs are more resistant to papain digestion than non-glycosylated IgGs (Biochem. Biophys. Res. Commun. 2006, 341, 797-803). To test whether specific Fc glycan structures affect Ab resistance to papain, we used in vitro glycoengineering methods to prepare homogeneous Ab glycoforms terminated with either sialic acid (G2S2), beta-galactose (G2), or N-acetylglucosamine (G0) and subjected them to papain digestions. Analyses of aliquots taken at different times during the digestions by matrix-assisted laser desorption-time-of-flight-mass spectroscopy (MALDI-TOF-MS) and high-performance liquid chromatography (HPLC) methods showed that the G0 glycoform was at least two times more resistant to papain digestion than the G2 and G2S2 glycoforms. The increased resistance of the G0 glycoform over the G2 and G2S2 glycoforms was independent of the specific Ab analyzed. A mouse/human chimeric version of Ab1, a fully human version of Ab2, and a humanized version of Ab3 exhibited a similar pattern of glycoform-dependent resistance. These data suggest that terminal sugars of Fc glycans may play important roles in Ab stability and affect resistance to proteases in addition to impacting Ab effector functions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17571902     DOI: 10.1021/bp070118k

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  20 in total

1.  The impact of glycosylation on monoclonal antibody conformation and stability.

Authors:  Kai Zheng; Christopher Bantog; Robert Bayer
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

2.  Engineering of Yeast Glycoprotein Expression.

Authors:  Charlot De Wachter; Linde Van Landuyt; Nico Callewaert
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

3.  Galactosylation variations in marketed therapeutic antibodies.

Authors:  T Shantha Raju; Robert E Jordan
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

4.  Rapid Fc glycosylation analysis of Fc fusions with IdeS and liquid chromatography mass spectrometry.

Authors:  Heather Lynaugh; Huijuan Li; Bing Gong
Journal:  MAbs       Date:  2013-06-20       Impact factor: 5.857

Review 5.  Modulating carbohydrate-protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology.

Authors:  Austin Wt Chiang; Shangzhong Li; Philipp N Spahn; Anne Richelle; Chih-Chung Kuo; Mojtaba Samoudi; Nathan E Lewis
Journal:  Curr Opin Struct Biol       Date:  2016-09-14       Impact factor: 6.809

Review 6.  Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

7.  High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation.

Authors:  Mohammad A Alsenaidy; Jae Hyun Kim; Ranajoy Majumdar; David D Weis; Sangeeta B Joshi; Thomas J Tolbert; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2013-09-24       Impact factor: 3.534

8.  Influence of glycosylation pattern on the molecular properties of monoclonal antibodies.

Authors:  Kai Zheng; Mark Yarmarkovich; Christopher Bantog; Robert Bayer; Thomas W Patapoff
Journal:  MAbs       Date:  2014-03-24       Impact factor: 5.857

Review 9.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

Review 10.  Effects of glycosylation on the stability of protein pharmaceuticals.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.